Press release
Sarcopenia Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
In the Sarcopenia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Sarcopenia Pipeline Report
• Sarcopenia Pipeline report offers a comprehensive analysis of 12+ companies and 14+ therapies.
• The leading Sarcopenia Companies includes Lipocine Inc., MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Oncocross Therapeutics, OPKO health, NMD Pharma, Rejuvenate Biomed, Immunoforge, Rubedo Life Sciences, Faraday Pharmaceuticals, Actimed Therapeutics, Pephexia Therapeutics, and others.
• Promising Sarcopenia Pipeline Therapies includes REGN1033 (SAR391786), bimagrumab, Astaxanthin formulation, bimagrumab, LPCN 1148, and others.
• The Sarcopenia companies and academics are working to assess challenges and seek opportunities that could influence Sarcopenia R&D. The Sarcopenia pipeline therapies under development are focused on novel approaches to treat/improve Sarcopenia.
Explore more information on the latest breakthroughs in the Sarcopenia treatment landscape of the report and Sarcopenia Pipeline Outlook @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Sarcopenia Overview
Sarcopenia is a musculoskeletal disease in which muscle mass, strength, and performance are significantly compromised with age. Sarcopenia most commonly affects elderly and sedentary populations and patients who have comorbidities that affect the musculoskeletal system or impair physical activity. The diagnosis of sarcopenia encompasses decreased levels of the following 3 traits: muscle strength, muscle quantity or quality, and physical performance. Causes of sarcopenia are generally attributable to the natural processes of aging, which are not entirely understood and are multifaceted. Risk factors for sarcopenia include age, gender and level of physical activity. The main treatment path for sarcopenia is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to people with sarcopenia.
Recent Development Activities in the Sarcopenia Treatment Landscape
In January 2022, MyMD Pharma announced that he U.S. Patent and Trademark Office (USPTO) awarded to the company U.S. Patent 11,219,620 B2, titled "Method of Treating Sarcopenia." The patent was issued on January 11, 2022. Currently it is being evaluated in Phase II clinical studies to treat patients with Sarcopenia.
Request a sample and discover the recent advances in Sarcopenia Pipeline Therapies, visit Sarcopenia Treatment Landscape @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Sarcopenia Pipeline Therapeutics Assessment
There are approx. 12+ key companies which are developing the therapies for Sarcopenia. The Sarcopenia companies which have their Sarcopenia drug candidates in the most advanced stage, i.e. phase III include, Biophytis.
Sarcopenia Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Get to know more information about the Sarcopenia Emerging Drugs and Sarcopenia Companies of the report @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Sarcopenia Pipeline Report
• Coverage- Global
• Companies- Lipocine Inc., MyMD Pharmaceuticals, Biophytis, Dystrogen Therapeutics, Oncocross Therapeutics, OPKO health, NMD Pharma, Rejuvenate Biomed, Immunoforge, Rubedo Life Sciences, Faraday Pharmaceuticals, Actimed Therapeutics, Pephexia Therapeutics, and others.
• Pipeline Therapies- REGN1033 (SAR391786), bimagrumab, Astaxanthin formulation, bimagrumab, LPCN 1148, and others.
• Sarcopenia Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Sarcopenia Market Drivers and Sarcopenia Market Barriers, click here Sarcopenia Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Sarcopenia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sarcopenia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sarconeos (BIO101): Biophytis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MYMD-1: MyMD Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. PF-1801: PhaseBio Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Sarcopenia Key Companies
21. Sarcopenia Key Products
22. Sarcopenia- Unmet Needs
23. Sarcopenia- Market Drivers and Barriers
24. Sarcopenia- Future Perspectives and Conclusion
25. Sarcopenia Analyst Views
26. Sarcopenia Key Companies
27. Appendix
Got Queries? Find out the related information on Sarcopenia Mergers and acquisitions, Sarcopenia Licensing Activities, and Click here for Sarcopenia Emerging Drugs, and Recent Trends @ https://www.delveinsight.com/sample-request/sarcopenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Trending Market Research Reports in 2023 By DelveInsight
Stem Cell Market- https://www.delveinsight.com/report-store/stem-cell-market
Anastomosis Device Market- https://www.delveinsight.com/report-store/anastomotic-leak-devices-market
Oncolytic virus cancer therapy pipeline- https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021
Persistent Corneal Epithelial Defects Market- https://www.delveinsight.com/report-store/persistent-epithelial-defect-market
Technical Due Diligence Firms | Technical Due Diligence Firms- https://www.delveinsight.com/consulting/due-diligence-services
Shingles Market- https://www.delveinsight.com/report-store/shingles-market
Hand Foot Syndrome/Palmar-Plantar Erythrodysesthesia Syndrome Market- https://www.delveinsight.com/report-store/hand-foot-syndrome-market
Ptosis Market- https://www.delveinsight.com/report-store/ptosis-market
Uncomplicated Urinary Tract Infection Market- https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
Otitis Media Market- https://www.delveinsight.com/report-store/otitis-media-market
Pelizaeus-Merzbacher Disease Market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Transverse Myelitis Market- https://www.delveinsight.com/report-store/transverse-myelitis-market
PCSK9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-market
Cough in IPF Market- https://www.delveinsight.com/report-store/cough-in-idiopathic-pulmonary-fibrosis-ipf-market
Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market
Advanced Liver Cancer Market- https://www.delveinsight.com/report-store/advanced-liver-cancer-market
Chagas Disease Market- https://www.delveinsight.com/report-store/chagas-disease-market
Familial Adenomatous Polyposis Market- https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-market
Metastatic Pancreatic Cancer Market- https://www.delveinsight.com/report-store/metastatic-pancreatic-cancer-mpc-market
Trichotillomania Market- https://www.delveinsight.com/report-store/trichotillomania-ttm-market
Temporomandibular Disorders Market- https://www.delveinsight.com/report-store/temporomandibular-disorders-market
Testicular Neoplasm Market- https://www.delveinsight.com/report-store/testicular-neoplasm-market
Joint Reconstruction Devices Market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Rhinosinusitis Market- https://www.delveinsight.com/report-store/rhinosinusitis-market
Atrial Flutter Market- https://www.delveinsight.com/report-store/atrial-flutter-market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcopenia Pipeline Appears Robust With 12+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 2903849 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Sarcopenia
Sarcopenia Market Size, Share & Growth Analysis 2034
Sarcopenia Market Overview
Sarcopenia is a condition characterized by the progressive loss of muscle mass, strength, and function, primarily affecting the elderly. This decline leads to increased frailty, higher risk of falls, and diminished quality of life. The rising global geriatric population has heightened the prevalence of sarcopenia, making it a significant public health concern. Consequently, there is a growing demand for effective treatments and interventions to manage and mitigate the…
Sarcopenia Treatment Market Future Prediction Report By 2030
Sarcopenia Treatment Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market dynamics.…
Sarcopenia Treatment Market Report 2024 - Sarcopenia Treatment Market Size And G …
"The Business Research Company recently released a comprehensive report on the Global Sarcopenia Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The sarcopenia treatment market…
Sarcopenia Pipeline Insights Report 2023 (Updated)
(Albany, United States) As per DelveInsight's assessment, globally, the Sarcopenia Pipeline constitutes 8+ key companies continuously working towards developing 10+ Sarcopenia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Sarcopenia Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Sarcopenia NDA approvals (if any), and product…
Global Sarcopenia Therapeutic Market Research Report 2023
The global Sarcopenia Therapeutic market was valued at US$ 2867.6 million in 2022 and is anticipated to reach US$ 3484.4 million by 2029, witnessing a CAGR of 3.3% during the forecast period 2023-2029.
view full report
https://reports.valuates.com/market-reports/QYRE-Auto-13K14453/global-sarcopenia-therapeutic
Sarcopenia Therapeutic Market
Sarcopenia is a syndrome caused by continuous loss of skeletal muscle mass, strength, and function.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
China is the largest consumption region of…
Sarcopenia - Drug Pipeline Landscape, 2022
Sarcopenia is a condition characterized by the loss of muscle mass and strength. It can occur due to a variety of reasons, including aging, inactivity, and certain chronic diseases.
Aging is the most common cause of sarcopenia. As people age, they tend to become less active and lose muscle mass. This process is known as age-related muscle loss or sarcopenia with aging.
Inactivity can also lead to sarcopenia. People who are not…
